

## Reach

### Diaceutics Announces Key Leadership Appointment

#### *Lauren DeWitt appointed General Counsel and Group Company Secretary*

**New York, Belfast and London, 29 July 2025** - **Diaceutics PLC** (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical and biotech industries, today announced the appointment of Lauren DeWitt as Executive Vice President, Legal, General Counsel, and Group Company Secretary. She will be based at the company's U.S. headquarters.

Lauren brings extensive legal and leadership experience in the pharmaceutical sector. Most recently, she served as Vice President and Head of General Legal at Sandoz, where she led a team of senior attorneys supporting all facets of the U.S. business, including commercial, regulatory, quality, medical affairs, and compliance.

Earlier in her career, Lauren held several key legal roles at both Sandoz and Novartis, including Global Head of Legal BD&L for Novartis Group, where she oversaw complex global transactions and strategic partnerships. She began her legal career as a litigator, representing healthcare and life sciences companies in product liability and general litigation matters.

**Ryan Keeling, Chief Executive Officer of Diaceutics commented:** "Lauren brings deep expertise across litigation, regulatory, and transactional legal functions, along with a strategic mindset that aligns perfectly with our growth ambitions. Her proven track record in leading high-impact legal teams and navigating complex global transactions makes her an invaluable addition to our leadership team."

**Lauren DeWitt, EVP Legal, General Counsel & Group Company Secretary of Diaceutics commented:** "I'm thrilled to be joining Diaceutics at such an exciting stage of its journey. I was drawn to the company's mission, the calibre of its legal and compliance work, and the opportunity to make a meaningful contribution to its continued success. I look forward to leading the legal function and supporting Diaceutics' strategic growth."

#### Enquiries:

##### Diaceutics PLC

Ryan Keeling, Chief Executive Officer  
Nick Roberts, Chief Financial Officer

Tel: +44 (0)28 9040 6500

[investorrelations@diaceutics.com](mailto:investorrelations@diaceutics.com)

##### Canaccord Genuity Limited (Nomad & Broker)

Tel: +44 (0)20 7523 8000

Simon Bridges, Andrew Potts, Harry Rees

#### About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

#### About Reach Announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAUVSORVRUBUAR